World’s First: BLOCKLORDS Becomes the First Web3 Game to Launch Its Game Truly Community First

World’s First: BLOCKLORDS Becomes the First Web3 Game to Launch Its Game Truly Community First

MetaKing Studios, the game developer focused on gaming, entertainment and fun community experiences for gamers, has released the Community-Beta version of its highly anticipated game, BLOCKLORDS, exclusively to their community first. 

The BLOCKLORDS community beta release is a significant milestone for the studio and showcases the scale of what they are building together with their community ahead of the full game launch. 

BLOCKLORDS is a multiplayer strategy game designed with a simple principle: “Fun Conquers All”. As part of a new generation of up-and-coming games, it uses innovative technology to create immersive experiences that give more control to the players. Using the latest simulations, graphics, and other technologies, BLOCKLORDS is creating an immersive world and giving players more opportunities to shape their stories.

The idea of scalable games and player-driven storylines is attractive to game investors as well. Named by Forbes as The Next-Gen Game That Big Players & Game Investors Are Backing, BLOCKLORDS, has already raised $15M in seed stage funding from big-name game giants like Square Enix, Krafton, Fun Plus, Makers Fund, BITKRAFT, Delphi Digital, Animoca Brands, ShimaCapital, and others. 

BLOCKLORDS has been pinned as a pioneering game for web3, but today MetaKing Studios is excited to reveal their most important partnership yet: Community. The studio recognizes the importance of community in the web3 ecosystem, which is why it decided to give its community a stake in the development process.

With BLOCKLORDS, MetaKing Studio is promising a high-fidelity gaming experience that takes full advantage of the capabilities of the web3 platform. By involving the community in the development process, the studio is not only able to ensure that the game will meet the needs and desires of its audience, but it’s also giving gamers a chance to participate in the development of the franchise in true web3 spirit, something that web2 gamers have been dreaming of for years.

The community beta release is just the beginning for BLOCKLORDS. With the help of its community, the studio plans to build out the game even further, incorporating feedback and ideas from its players to create a finished product that truly delivers on its promises. 

“By working together with our team, partners, friends, and our dedicated community of gamers, we can create truly groundbreaking experiences that push the limits of what’s been possible before in the world of gaming. The success of BLOCKLORDS is a testament to the value of community in the development of immersive, engaging, and innovative games that put players at the forefront.” – David Johansson, Creator of BLOCKLORDS. 

 You can play BLOCKLORDS for free by joining the Community Beta and claiming your free in-game hero at www.blocklords.com

About BLOCKLORDS 

Featuring a fully-owned economy, BLOCKLORDS is a medieval MMO strategy game. There are a variety of roles players can play within the BLOCKLORDS universe, all with distinct yet intertwined responsibilities. In BLOCKLORDS, players can craft their own unique stories within a shared universe based on a strong franchise/brand foundation. In this medieval metaverse, players will be able to shape their kingdom to the highest level by farming, fighting, and ruling, making it the first of its kind for web3.

Website |Discord | Twitter | Telegram | LinkedIn

Contact Information:

Sam Rowlands

[email protected]

Press Contact

MetaKing Studios

[email protected]

Original Source:

World’s First: BLOCKLORDS Becomes the First Web3 Game to Launch Its Game Truly Community First

Continue Reading

LUXILΛN Transforms from Humble Beginnings to Global Skincare Powerhouse

LUXILΛN Transforms from Humble Beginnings to Global Skincare Powerhouse

Company has been dedicated to personalized skincare and unrelenting innovation since 1996 CHINA, May 8, 2023/EINPresswire.com/ — LUXILΛN, one of the most iconic and beloved cosmetics brands in China, is proud to showcase its journey from a small company with just four products to an international powerhouse with a wide range of skincare offerings. Founded […]

The post LUXILΛN Transforms from Humble Beginnings to Global Skincare Powerhouse first appeared on Beauty Ring Magazine.

Continue Reading

FarmaKeio Outsourcing Announces Patented Formulation of Revolutionary Hormone Therapy Pellet

FarmaKeio Outsourcing Announces Patented Formulation of Revolutionary Hormone Therapy Pellet

FarmaKeio Outsourcing is proud to announce the release of its latest innovation, the only patented hormone pellet with triamcinolone developed in an FDA-registered 503B outsourcing facility. The pellet is set to provide a new and revolutionary solution to hormone replacement therapy for men and women.

FarmaKeio Outsourcing Announces Patented Formulation of Revolutionary Hormone Therapy Pellet
The patented hormone pellet formulated with an anti-inflammatory for better outcomes.

FarmaKeio Outsourcing’s patented pellet is developed in an FDA-registered 503B facility and distinctly designed to deliver a more comfortable treatment option to patients.

FarmaKeio Outsourcing (FKO), a leading pharmaceutical outsourcing facility in the United States, has been granted a patent to produce testosterone and triamcinolone subcutaneous hormone pellets. The patent includes 23 claims, issued by the United States Patent and Trademark Office (USPTO), recognizing the company’s innovative approach to compounding hormone therapy and solidifying its position as a leader in the field of pharmaceutical development.

Unlike other hormone therapies, which may require frequent injections or daily pills, FarmaKeio Outsourcing’s hormone pellets provide a sustained release of testosterone and triamcinolone, allowing patients to enjoy the benefits of these hormones for extended periods of time. These pellets are inserted subcutaneously and gradually release the hormone over several months, reducing the need for frequent dosing and allowing patients to focus on their daily lives.

“We are thrilled to receive this patent for our subcutaneous hormone pellets,” said FarmaKeio Outsourcing’s CEO, Dan DeNeui. “Our team has worked tirelessly to develop this innovative approach to hormone therapy, and we are excited to be able to offer this option to patients in need.”

In addition to providing a more convenient method of hormone therapy, FarmaKeio’s pellets offer a unique formulation that is not available from any other FDA 503B registered outsourcing facility in the US. This proprietary formulation has been carefully designed and tested and it represents a significant breakthrough in the field of hormone therapy.

“We believe that our hormone pellets have the potential to revolutionize the way that hormone therapy is delivered,” said DeNeui. “By offering a sustained release of testosterone and triamcinolone, we can provide patients with a more consistent and reliable treatment option that can improve their quality of life.”

The issuance of this patent is a significant milestone for FarmaKeio Outsourcing, and it reflects the company’s ongoing commitment to innovation and excellence in pharmaceutical development. As the demand for hormone therapy continues to grow, FarmaKeio is well-positioned to meet the needs of patients and healthcare providers alike with its cutting-edge hormone pellets.

“We are confident that our hormone pellets will become the gold standard for hormone therapy, and we look forward to working with healthcare providers and patients to make this technology available to as many people as possible,” said Chief Operating Officer Cody Boatman.

The hormone pellet with triamcinolone is a groundbreaking new product that is set to revolutionize the hormone replacement therapy industry. With its unique combination of hormones and anti-inflammatory properties, it provides patients with a more comfortable treatment option. The pellet is an exclusive feature of The EvexiPEL Method, created and founded by Terri DeNeui, DNP, APRN, ACNP-BC, and is available exclusively through FarmaKeio Outsourcing, an FDA-registered 503B facility. With this new product, FarmaKeio Outsourcing is once again proving its commitment to providing innovative solutions to hormone replacement therapy.

About FarmaKeio Outsourcing 

FarmaKeio Outsourcing is a leading FDA-registered 503B pharmaceutical outsourcing facility that specializes in providing specific custom compounded medications to healthcare providers and facilities across the United States. FarmaKeio Outsourcing is committed to providing innovative, patient-centered solutions that meet the unique needs of their clients.

FarmaKeio Outsourcing offers an unwavering commitment to quality, safety, and compliance, operating a state-of-the-art facility that is cGMP compliant and undergoes rigorous testing and quality assurance procedures to ensure the highest level of quality and safety.

FarmaKeio Outsourcing provides exceptional customer service and support, ensuring that their clients have access to the resources and expertise necessary to make informed decisions about patient care. FarmaKeio Outsourcing is a trusted partner for healthcare providers looking to offer the most innovative and advanced care solutions to their patients.

Contact Information:

Danielle Tworek

Director of Marketing

[email protected]

5613253904

Original Source:

FarmaKeio Outsourcing Announces Patented Formulation of Revolutionary Hormone Therapy Pellet

The post FarmaKeio Outsourcing Announces Patented Formulation of Revolutionary Hormone Therapy Pellet first appeared on Enrose Magazine.

Continue Reading

Avere Beauty Now Offering Cryoskin Treatments at Its MedSpas in Pittsburgh

Avere Beauty Now Offering Cryoskin Treatments at Its MedSpas in Pittsburgh

There are many reasons why CryoSkin body contouring, slimming and toning, and facials are so popular. PITTSBURGH, PENNSYLVANIA, UNITED STATES, May 8, 2023/EINPresswire.com/ — Thanks to the tremendous advancements in safe, effective, and reliable medspa science and techniques, it is now easy and safe to lose inches fast, sculpt abs and legs, and improve the […]

The post Avere Beauty Now Offering Cryoskin Treatments at Its MedSpas in Pittsburgh first appeared on Beauty Ring Magazine.

Continue Reading

pixiv to sponsor ‘SSS by applibot’ exhibition ‘Re\arise #1.6 EXHIBITION L.A.’ featuring members BUNBUN, Mai Yoneyama, and PALOW

pixiv to sponsor ‘SSS by applibot’ exhibition ‘Re\arise #1.6 EXHIBITION L.A.’ featuring members BUNBUN, Mai Yoneyama, and PALOWSupporting creators expanding overseas

pixiv, the communications platform operated by pixiv Inc. (hereinafter referred to as “pixiv”, Office: Shibuya, Tokyo, Representative Director: Shingo Kunieda), where users can share illustrations, manga, and novels, will be the corporate sponsor of the exhibition “Re\arise #1.6 EXHIBITION L.A.”, which opens on May 27, 2023, at Gallery Nucleus in Los Angeles, California, USA, and features works by the creative collective “SSS by applibot”.

“Re\arise #1.6 EXHIBITION L.A.” Official Website: https://rearise.sss.applibot.co.jp/1_6la/en/

pixiv aims to help creators expand overseas through sponsorship
“SSS by applibot” includes a total of eight celebrity creators (BUNBUN, Naji Yanagida, PALOW, Sevnzel, taiki, Isssai, Masafumi Takagi, and Mai Yoneyama) who create games, anime, light novels and more. 

About SSS by applibot: https://sss.applibot.co.jp/

pixiv has long been actively involved in promoting creators overseas and helping Japanese creators expand internationally. pixiv highly values its ongoing partnership with “SSS by applibot”, and is proud to support their members at this all-new U.S. exhibition as the official corporate sponsor.

pixiv’s support for creators overseas
As of April 2023, pixiv boasted more than 90 million registered users, of whom 58% are located outside Japan. Of pixiv’s non-Japanese members, about 7.2 million are located in the USA, with more than 1.1 million unique users from the USA using the pixiv site each month. American creators have posted a cumulative total of more than 3.7 million pages of works to the site.

In December of last year, pixiv partnered with the U.S.-based publisher Clover Press to release English editions of “Artists in Taiwan” and “Artists in Korea”, which highlight the work of creators in those countries. This crowdfunded project garnered a total of $88,524 in financing on Kickstarter, becoming a hugely successful project for introducing works by Asian creators into the Western market.

Then, in March of this year, pixiv partnered with the publisher PIE International to release an artbook entitled “Artists in the Americas”, showcasing work by 62 creators from North and South America to proactively support creators from the Americas and help them deepen their relationships with their fans.

Going forward, pixiv will continue to support creative activities and produce opportunities to help creators expand their fanbase internationally.

■ About pixiv https://www.pixiv.net
pixiv is a social networking service for creators, focused on “communication through sharing works”. 

■ pixiv, Inc. https://www.pixiv.co.jp
Striving to be an exciting space for users to enjoy creative activities, we provide various services to support creators, including pixiv, one of the world’s largest art communities, FANBOX, encouraging creators’ activities, and the 3D project VRoid.

Representative Director: Shingo Kunieda
Established: July 25th, 2005
Inquiries: Takahashi, Nishidoi
E-mail: [email protected]

Contact Information:

Mika Nishidoi

editor

[email protected]

Original Source:

pixiv to sponsor ‘SSS by applibot’ exhibition ‘Re\arise #1.6 EXHIBITION L.A.’ featuring members BUNBUN, Mai Yoneyama, and PALOW

Continue Reading